EUVIMEDEUVIMED entdecken
Crossref

LI-RADS version 2018 treatment response algorithm on extracellular contrast-enhanced MRI in patients treated with transarterial chemoembolization for hepatocellular carcinoma: diagnostic performance and the added value of ancillary features

Di Wang, Yang Zhang, Rong Lyu, Kefeng Jia, Peng-Ju Xu iD

Abdominal Radiology · 2024

DOI: 10.1007/s00261-024-04275-y ↗

Kurz gefasst

Fachartikel in der Zeitschrift Abdominal Radiology, 2024. Verfasst von Di Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Tianjin Third Central Hospital, Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Artificial Cell…. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular, Algorithms, Chemoembolization, Therapeutic. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The Liver Imaging Reporting and Data System (LI-RADS) Treatment Response Algorithm (TRA) (LI-RADS TRA) is used for assessing response of HCC to locoregional therapy (LRT), however, the value of ancillary features (AFs) for TACE-treated HCCs has not been extensively investigated on extracellular agent MRI (ECA-MRI). PURPOSE: To evaluate the diagnostic performance of LI-RADS v2018 TRA on ECA-MRI for HCC treated with transarterial chemoembolization (TACE) and the value of ancillary features. METHODS: This retrospective study included patients who underwent TACE for HCC and then followed by hepatic surgery between January 2019 and June 2023 with both pre- and post-TACE contrast-enhanced MRI available. Two radiologists independently evaluated the post-treated lesions on MRI using LI-RADS treatment response (TR) (LR-TR) algorithm and modified LR-TR (mLR-TR) algorithm in which ancillary features (restricted diffusion and intermediate T2-weighted hyperintensity) were added, respectively. Lesions were categorized as complete pathologic necrosis (100%, CPN) and non-complete pathologic necrosis (< 100%, non-CPN) on the basis of surgical pathology. The diagnostic performance in predicting viable and non-viable tumors based on LR-TR and mLR-TR algorithms was compared using the McNemar test. Interreader agreement was calculated by using Cohen's weighted and unweighted κ. RESULTS: A total of 61 patients [mean age 59 years ± 10 (standard deviation); 47 men] with 79 lesions (57 pathologically viable) were included. For non-CPN prediction, the sensitivity, specificity of LR-TR viable and mLR-TR viable category were 75% (43 of 57), 82% (18 of 22) and 88% (50 of 57), 77% (17 of 22), respectively, the sensitivity of mLR-TR was significantly higher than that of LR-TR (P = 0.016) without difference in specificity (P = 1.000). Interreader agreement for LR-TR and mLR-TR category was moderate (k = 0.50, 95% confidence interval 0.33, 0.67, k = 0.42, 95% confidence interval 0.20, 0.63). The sensitivity of both LR-TR and mLR-TR algorithms in predicting viable tumors between conventional TACE (cTACE) and drug-eluting beads TACE (DEB-TACE) did not have significant difference (cTACE: 76%, 89% vs. DEB-TACE: 73%, 82%). CONCLUSIONS: On ECA-MRI, applying ancillary features to LI-RADS v2018 TRA can improve the sensitivity in predicting pathologic tumor viability in patients treated with TACE for hepatocellular carcinoma with no significant difference in specificity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver NeoplasmsCarcinoma, HepatocellularAlgorithmsChemoembolization, TherapeuticMagnetic Resonance ImagingContrast MediaHumansMaleFemaleRetrospective StudiesMiddle AgedAgedTreatment OutcomeAdultSensitivity and Specificity

Stichwörter der Autor:innen

Hepatocellular carcinomaLiver imaging reporting and data system (LI-RADS)Treatment responseWashout

Substanzen

Contrast Media

Autor:innen und Institutionen

  • Department of Radiology, Tianjin Third Central Hospital, Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Artificial Cell Engineering Technology Research Center, Tianjin Institute of Hepatobi…
  • Department of Radiology, Zhongshan Hospital, Fudan University, No. 180 Fenglin Road, Xuhui District, Shanghai, 200032, China.
  • Department of Radiology, Dongying People's Hospital Shandong, Dongying, China.
  • Department of Radiology, Zhongshan Hospital, Fudan University, No. 180 Fenglin Road, Xuhui District, Shanghai, 200032, China. xpjbfc@163.com.
  • Shanghai Institute of Medical Imaging, No. 180 Fenglin Road, Xuhui District, Shanghai, 200032, China. xpjbfc@163.com.

ORCID-Profile: Peng-Ju Xu

Zitieren

APA

Wang, D., Zhang, Y., Lyu, R., Jia, K., & Xu, P. J. (2024). LI-RADS version 2018 treatment response algorithm on extracellular contrast-enhanced MRI in patients treated with transarterial chemoembolization for hepatocellular carcinoma: diagnostic performance and the added value of ancillary features. Abdominal Radiology. https://doi.org/10.1007/s00261-024-04275-y

Vancouver

Wang D, Zhang Y, Lyu R, Jia K, Xu PJ. LI-RADS version 2018 treatment response algorithm on extracellular contrast-enhanced MRI in patients treated with transarterial chemoembolization for hepatocellular carcinoma: diagnostic performance and the added value of ancillary features. Abdominal Radiology. 2024. doi:10.1007/s00261-024-04275-y

BibTeX
@article{Wang2024,
  author = {Wang, Di and Zhang, Yang and Lyu, Rong and Jia, Kefeng and Xu, Peng-Ju},
  title = {LI-RADS version 2018 treatment response algorithm on extracellular contrast-enhanced MRI in patients treated with transarterial chemoembolization for hepatocellular carcinoma: diagnostic performance and the added value of ancillary features},
  journal = {Abdominal Radiology},
  year = {2024},
  doi = {10.1007/s00261-024-04275-y}
}
Kostenlos starten →